GLP-1 for Fatty Liver Disease

Summary: In August 2025 the FDA approved Wegovy as the first GLP-1 medication for MASH with moderate-to-advanced fibrosis, based on the Phase 3 ESSENCE trial that resolved steatohepatitis in 63% of treated patients versus 34% on placebo.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: yes, GLP-1 medications work for fatty liver disease, and as of August 2025 there is an FDA-approved option. Wegovy (semaglutide 2.4 mg) is approved for adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced liver fibrosis ^[1]. Tirzepatide is not yet approved for this indication, but the Phase 3 SYNERGY-NASH trial showed comparable benefit ^[3]. Both work through the same dominant mechanism: substantial weight loss, plus likely direct hepatic effects that researchers are still mapping.

This page covers what the trials actually showed, the difference between MASLD and MASH (the terminology changed in 2023 and most patients are confused about it), who qualifies under the FDA label, and what to expect during treatment.

MASLD vs MASH: why the terminology changed

In 2023, hepatology societies retired the term "nonalcoholic fatty liver disease" (NAFLD) and replaced it with "metabolic dysfunction-associated steatotic liver disease" (MASLD). The reasoning: the old name defined the condition by what it was not (not caused by alcohol), and that framing missed the point. The disease is driven by metabolic dysfunction. Insulin resistance, central obesity, dyslipidemia, type 2 diabetes. Naming it after the actual cause matches modern understanding.

The progression looks like this:

MASLD is the umbrella. MASH is the inflammatory subtype that progresses to cirrhosis, liver cancer, transplant, or death. Roughly 25 to 30% of US adults have MASLD. About 6% of US adults (close to 15 million people) have MASH specifically ^[1]. The FDA approval of Wegovy targets the MASH population with stage 2 to 3 fibrosis, not the broader MASLD pool.

The ESSENCE trial: how Wegovy got approved for MASH

The FDA decision rested on ESSENCE, a Phase 3 randomized trial conducted by Novo Nordisk. The planned 72-week interim analysis enrolled 800 adults with biopsy-confirmed MASH and stage 2 or 3 fibrosis. Two-to-one randomization: 534 patients on semaglutide 2.4 mg weekly, 266 on placebo. Both arms continued lifestyle counseling. The primary endpoint was histologic, meaning a second liver biopsy at 72 weeks compared to baseline ^[1][2].

The headline results:

• MASH resolution without worsening fibrosis: 63% of semaglutide patients vs 34% of placebo patients
• Fibrosis improvement of at least one stage without worsening MASH: 37% of semaglutide vs 22% of placebo
• Both endpoints met simultaneously: roughly one-third of treated patients ^[2][4]

The trial also reported improvements in ALT, AST, non-invasive fibrosis markers, body weight, and cardiometabolic risk factors. Average weight loss in the semaglutide arm was in the 10 to 12% range, consistent with the STEP weight-management trials.

Approval came under the accelerated pathway. That means the FDA accepted histologic improvement as a surrogate for long-term outcomes (death, transplant, hepatic decompensation), and Novo Nordisk has to keep ESSENCE running through week 240 to confirm that surrogate translates into hard outcomes ^[1]. If those numbers fail to materialize, the FDA can withdraw approval. That is a remote scenario given the strength of the interim data, but it is the regulatory reality.

SYNERGY-NASH: tirzepatide produced similar results

Tirzepatide is not approved for MASH yet, but it has the data to support an approval application. SYNERGY-NASH was a Phase 2 trial published in NEJM in 2024 that randomized 190 patients with biopsy-confirmed MASH and stage F2 or F3 fibrosis to tirzepatide 5 mg, 10 mg, 15 mg, or placebo for 52 weeks ^[3].

MASH resolution without worsening fibrosis:

• Placebo: 10%
• Tirzepatide 5 mg: 44%
• Tirzepatide 10 mg: 56%
• Tirzepatide 15 mg: 62%

The 15 mg arm matched semaglutide's ESSENCE numbers almost exactly. Fibrosis improvement also trended in tirzepatide's favor, though that endpoint did not reach statistical significance, similar to early semaglutide data. Lilly has a Phase 3 program underway. An FDA decision for tirzepatide in MASH is plausible in the 2027 to 2028 window.

For now, doctors who want to prescribe tirzepatide for MASH are doing so off-label. Insurance will not cover the indication. Patients who use Mounjaro or Zepbound for diabetes or weight management with concurrent MASH are getting the liver benefit incidentally, and the published trial data supports that.

Why GLP-1 works for the liver: mechanism

The short version: weight loss is the main lever, and direct hepatic effects are likely a supporting one.

Liver fat accumulates when intake (dietary fat, lipogenesis from sugar, fatty acid delivery from adipose tissue) exceeds export (oxidation, VLDL secretion). Insulin resistance jams the export pathways and drives lipogenesis. Visceral fat (the kind that wraps your organs) is metabolically active and feeds inflammatory signals directly to the liver via portal circulation.

GLP-1 receptor agonists hit this loop at several points:

1. Appetite suppression and caloric reduction. Less food in means less substrate for hepatic fat synthesis. Weight loss of 7 to 10% reliably improves steatosis. Weight loss above 10% improves inflammation and can resolve MASH histologically. The ESSENCE patients averaged 10 to 12% loss.
2. Improved insulin sensitivity. GLP-1 agonists improve glucose-stimulated insulin secretion and reduce hepatic glucose output. Better insulin signaling unjams the lipid export machinery.
3. Reduced visceral adiposity. GLP-1-driven weight loss preferentially removes visceral fat, which disproportionately drives liver inflammation through the portal vein.
4. Possible direct hepatic effects. GLP-1 receptors are expressed at low levels in liver cells. Researchers have proposed mechanisms involving mitochondrial function, oxidative stress, and inflammatory pathway modulation. The evidence is suggestive, not definitive. The FDA label cautiously notes "potentially other mechanisms not fully understood" alongside weight loss ^[1].

The question of how much of the benefit is weight loss versus direct action matters because it affects who responds. Some MASH patients are lean. Lean MASH is real, accounts for perhaps 10 to 20% of cases, and is often driven by genetic variants (PNPLA3, TM6SF2) plus metabolic dysfunction without overt obesity. If GLP-1 works purely through weight loss, lean MASH patients may not benefit much. If direct hepatic effects are real, they might. The ESSENCE subgroup analyses on this question are still maturing.

Does GLP-1 affect liver enzymes?

Yes, and the direction is favorable for fatty liver patients. ALT and AST levels reflect hepatocellular injury. In MASLD and MASH, they are typically elevated. GLP-1 treatment drives them down within weeks to months as liver fat clears and inflammation reduces. This is one of the easiest treatment-response markers to track. A drop from, say, ALT 80 to ALT 35 over six months of semaglutide is a strong signal that the liver is improving.

That is a different question from "does GLP-1 damage the liver." Hepatotoxicity from semaglutide and tirzepatide is rare. Routine FDA labels for both drugs do not require special liver monitoring outside the standard precautions. Cases of liver injury have been reported and investigated, but the population-level signal is neutral to favorable. The drugs are not metabolized primarily through the liver in the way that, say, acetaminophen is. They are peptides that get cleared by proteolytic enzymes throughout the body, with kidney involvement in elimination. So the answer to "are GLP-1 agonists metabolised through the liver" is largely no, which is part of why hepatic adverse events are uncommon.

Who qualifies for Wegovy under the MASH indication

The FDA label is specific. To qualify on-indication for Wegovy in MASH, a patient needs:

• Diagnosis of MASH (steatosis plus inflammation plus hepatocyte injury, typically confirmed by liver biopsy, though non-invasive markers are increasingly used in practice)
• Moderate-to-advanced fibrosis, meaning stage F2 or F3 on the standard scale
• No cirrhosis (F4). The trials excluded cirrhotic patients, and the approval does not cover them
• Adult age (18+)

In real-world practice, the bottleneck is fibrosis staging. Liver biopsy is the gold standard but it is invasive. Most patients get staged with non-invasive tools: FibroScan (transient elastography), MR elastography, the FIB-4 score, or the enhanced liver fibrosis (ELF) panel. A FibroScan reading of 8 to 12 kPa roughly corresponds to F2 to F3. Above 12 kPa raises suspicion of F4 and prompts biopsy or imaging-based confirmation. Insurance prior authorizations for Wegovy in MASH will likely require documentation of fibrosis stage by one of these methods.

What to expect during treatment

Patients starting Wegovy for MASH go through the same titration as patients starting it for obesity: 0.25 mg weekly for four weeks, then 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg as maintenance. The titration exists to manage GI side effects (nausea, vomiting, constipation, diarrhea) that are dose-dependent. About 70 to 80% of patients tolerate the full dose without quitting; the dropout rate in ESSENCE was modest.

Expect:

• Weeks 1 to 8: Appetite suppression begins, weight starts dropping, GI side effects most prominent during dose escalation
• Months 3 to 6: Weight loss accelerates, liver enzymes (ALT, AST) typically improve, FibroScan score may begin to drop
• Months 6 to 12: Plateau weight loss in the 10 to 15% range, steatosis on imaging substantially improved
• Months 12 to 24: Fibrosis remodeling (if it happens) shows up. Fibrosis improvement is slower than fat clearance. The ESSENCE 72-week endpoint is when this becomes statistically detectable

Monitoring during treatment commonly includes liver enzymes every 3 months for the first year, A1c every 3 months for diabetic patients, and a repeat FibroScan or MR elastography at 12 to 18 months to assess treatment response. Repeat biopsy is rare outside of trials.

Treatment is open-ended. If you stop the drug, the appetite suppression goes away within weeks, weight tends to return, and the liver disease tends to return with it. The MASH indication is not a 6-month course. It is a chronic therapy, similar to how statins or antihypertensives are chronic.

GLP-1 with liver disease: safety summary

For MASLD and non-cirrhotic MASH, GLP-1 receptor agonists are well-tolerated and the benefits are clear. The safety profile is the standard one: GI side effects, rare pancreatitis (incidence around 0.1 to 0.2%), increased gallstone risk during rapid weight loss, boxed warning for medullary thyroid carcinoma in patients with personal or family history. None of these are unique to liver disease patients.

For compensated cirrhosis, GLP-1 use for diabetes or obesity is generally considered acceptable but should be guided by hepatology. For decompensated cirrhosis, GLP-1 is typically avoided. Patients on the liver transplant list or post-transplant require specialist guidance; GLP-1 can interact with immunosuppression management and weight changes affect candidacy decisions.

Comparing GLP-1 to other fatty liver treatments

The treatment landscape changed twice in 18 months. Before March 2024, no drug was approved for MASH. In March 2024, the FDA approved resmetirom (Rezdiffra), a thyroid hormone receptor-beta agonist that works directly on the liver to reduce hepatic fat. In August 2025, Wegovy joined the list. Two approved drugs, two different mechanisms.

About metformin specifically: it does not improve fatty liver disease on histologic endpoints despite the metabolic benefit. Multiple trials and meta-analyses have looked at metformin for NASH and found no significant effect on liver fat, inflammation, or fibrosis. Metformin remains useful for diabetes, but it is not a fatty liver treatment in its own right.

The choice between resmetirom and semaglutide will often depend on the patient's profile. A patient with MASH and concurrent obesity or type 2 diabetes is a natural fit for semaglutide. A patient who already has well-controlled metabolic parameters at a normal weight but biopsy-proven MASH may be a better fit for resmetirom, which targets the liver without the weight-loss requirement. Some patients may end up on both, though combination data is limited.

Fatty liver and obesity treatment: how the populations overlap

About 75% of patients with obesity have MASLD. About 80 to 90% of patients with type 2 diabetes have MASLD. The diseases share their root cause: insulin resistance and metabolic dysfunction. Treating one almost always improves the other. The 2025 Wegovy approval formalizes what hepatologists and endocrinologists have observed clinically for years. The drug that pulls 15% of body weight off also pulls fat out of the liver and quiets the inflammation that causes scarring.

That overlap is why the AASLD welcomed the approval as "an exciting turning point in how we approach liver disease treatment" and tied it explicitly to integrated metabolic care ^[4]. Liver disease is not a separate condition that develops in isolation. It is metabolic dysfunction expressed in the liver. The pharmacology that works for the metabolic root works for the hepatic expression.

Common questions about GLP-1 for fatty liver disease

Does GLP-1 help fatty liver disease?

Yes. Wegovy is FDA-approved as of August 2025 for MASH with stage 2 to 3 fibrosis. In the ESSENCE trial, 63% of semaglutide-treated patients achieved MASH resolution without worsening fibrosis versus 34% on placebo.

Is GLP-1 bad for your liver?

No. Semaglutide and tirzepatide have favorable hepatic safety profiles. They are peptides cleared mostly outside the liver. Rare cases of drug-induced liver injury have been reported but population-level signals are neutral to favorable.

Does GLP-1 affect liver enzymes?

Yes, and in a good way for fatty liver patients. ALT and AST typically drop within weeks to months as liver fat clears. A 50% reduction in ALT over six months of treatment is common.

How does GLP-1 affect the liver?

Primarily through weight loss, which removes substrate for hepatic fat synthesis and improves insulin sensitivity. Possible direct effects on hepatic mitochondria and inflammation are being studied. The FDA label acknowledges both mechanisms.

What is the difference between MASLD and MASH?

MASLD is fat in the liver without significant inflammation. MASH is MASLD plus inflammation and hepatocyte injury, which can progress to fibrosis and cirrhosis. MASH is the inflammatory subtype, roughly 6% of US adults, and is the FDA-approved indication for Wegovy.

Is tirzepatide approved for fatty liver disease?

Not yet. SYNERGY-NASH (Phase 2) showed tirzepatide 15 mg matched semaglutide's MASH resolution rate. Lilly has Phase 3 trials running. FDA approval is plausible in 2027 to 2028. Off-label use for patients with concurrent diabetes or obesity is common.

Can I use GLP-1 if I have cirrhosis?

The Wegovy MASH approval excludes cirrhotic patients (stage F4). GLP-1 use for diabetes or obesity in compensated cirrhosis is acceptable under hepatology guidance. Decompensated cirrhosis is usually a contraindication. Get specialist input.

Will metformin help fatty liver?

Not directly. Metformin improves metabolic parameters but multiple trials have failed to show benefit on liver biopsy endpoints (fat, inflammation, fibrosis). It is useful for diabetes but is not a fatty liver treatment.

Are GLP-1 agonists metabolised through the liver?

Mostly no. Semaglutide and tirzepatide are peptides degraded by proteolytic enzymes throughout the body, with kidney involvement in clearance. Hepatic metabolism is minor, which is one reason they have favorable safety profiles in liver disease.

How long until I see liver improvement on GLP-1?

Liver enzymes often drop within 2 to 3 months. Steatosis on imaging improves at 6 to 12 months. Fibrosis remodeling takes 12 to 24 months and is the slowest endpoint. The ESSENCE biopsy endpoint was assessed at 72 weeks.

Bottom line

GLP-1 for fatty liver disease is no longer experimental. Wegovy has an FDA label for MASH with stage 2 to 3 fibrosis, the ESSENCE trial showed roughly 30 percentage points of separation from placebo on the histologic primary endpoint, and tirzepatide's Phase 2 data points to a likely future approval. The drug class works by addressing the metabolic dysfunction that drives the disease, with weight loss as the dominant mechanism and likely direct hepatic effects as a supporting one. For the right patient (MASH with significant fibrosis, no cirrhosis, candidate for the standard titration), this is now first-line pharmacotherapy alongside resmetirom. For patients with MASLD without significant fibrosis, treatment remains lifestyle-first, with GLP-1 considered when concurrent obesity or diabetes provides a separate indication.